PE20001552A1 - Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo - Google Patents

Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo

Info

Publication number
PE20001552A1
PE20001552A1 PE2000000184A PE0001842000A PE20001552A1 PE 20001552 A1 PE20001552 A1 PE 20001552A1 PE 2000000184 A PE2000000184 A PE 2000000184A PE 0001842000 A PE0001842000 A PE 0001842000A PE 20001552 A1 PE20001552 A1 PE 20001552A1
Authority
PE
Peru
Prior art keywords
cr5r5
prostaglandin
osteoporosis
alkyl
prostanoid
Prior art date
Application number
PE2000000184A
Other languages
English (en)
Inventor
Mitchell Anthony Delong
James Richard Hartke
Mark Walden Lundy
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20001552A1 publication Critical patent/PE20001552A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

SE REFIERE AL USO DE UN AGONISTA DE PROSTANOIDE E SUBTIPO 1 (EP1) QUE NO OCURRE NATURALMENTE SELECTIVO PARA EL RECEPTOR EP1 SOBRE OTROS RECEPTORES DE PROSTAGLANDINA EXCITATORIOS Y ADICIONALMENTE SELECTIVO SOBRE OTROS RECEPTORES DE PROSTANOIDES EN UNA RELACION DE 10:1; TAL COMO UN ANALOGO DE PROSTAGLANDINA DE FORMULA I, DONDE: R1 ES CO2H, CONHOH, CO2R3, CH2OH, SO2R3, CONHR3; R3 ES ALQUILO, HETEROALQUILO, CARBOCICLO, HETEROCICLO, ANILLO AROMATICO O HETEROAROMATICO; X ES CH2, O; R2 ES H, ALQUILO; W ES [CR5R5]m-Y-[CR5R5]n-Z, [CR5R5]p-U-[CR5R5]q; R5 ES H, ALQUILO, ALCOXI, HALO; m ES 0-1; n ES 0-1; Y ES CR5R5, NH, S, UN ENLACE; Z ES FENILO, TIENILO, FURANILO, p ES 0-3; q ES 1-3; p+q ES 1-4; U ES CR5R5, NH, S; O 17-FENIL-17-TRINOR PROSTAGLANDINA E2; 9-METILEN-9-DEOXI PROSTAGLANDINA 2; 9-METILEN-9-DEOXI-16,16-DIMETILO PROSTAGLANDINA E2; EL USO DEL AGONISTA DE PROSTANOIDE ES MEDIANTE UNA COMPOSICION TRANSDERMICA POR LO QUE PUEDE SER UTIL PARA AUMENTAR EL VOLUMEN OSEO, AUMENTAR EL VOLUMEN TRABECULAR, TRATAMIENTO DE LA OSTEOPOROSIS, OSTEOPOROSIS POSMENOPAUSICA, OSTEOARTRITIS, ENFERMEDAD DE PAGET, OSTEOMALACIA, FRACTURA OSEA
PE2000000184A 1999-03-05 2000-03-03 Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo PE20001552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
PE20001552A1 true PE20001552A1 (es) 2001-01-30

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000184A PE20001552A1 (es) 1999-03-05 2000-03-03 Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo

Country Status (10)

Country Link
EP (1) EP1158969A2 (es)
JP (1) JP2002538105A (es)
AU (1) AU3711900A (es)
CA (1) CA2366755A1 (es)
CO (1) CO5150205A1 (es)
IL (1) IL145128A0 (es)
NO (1) NO20014192L (es)
NZ (1) NZ513828A (es)
PE (1) PE20001552A1 (es)
WO (1) WO2000051585A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080000647A (ko) 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제
US8410171B2 (en) 2006-10-26 2013-04-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
EP2305304A4 (en) 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine IMMUNOSTIMULATOR WITH EP1 AGONIST
WO2011109729A2 (en) * 2010-03-05 2011-09-09 University Of Rochester Ep1 inhibition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
AU2146592A (en) * 1991-05-29 1993-01-08 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
ID24827A (id) * 1997-09-09 2000-08-24 Procter & Gamble Metoda peningkatan volume tulang dengan menggunakan agonis fp selektif yang terjadi secara non-alami
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
CA2366755A1 (en) 2000-09-08
NO20014192L (no) 2001-11-05
IL145128A0 (en) 2002-06-30
CO5150205A1 (es) 2002-04-29
NO20014192D0 (no) 2001-08-29
WO2000051585A2 (en) 2000-09-08
AU3711900A (en) 2000-09-21
EP1158969A2 (en) 2001-12-05
NZ513828A (en) 2001-09-28
JP2002538105A (ja) 2002-11-12
WO2000051585A3 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
RS39604A (en) Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
NZ525700A (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
PE20020637A1 (es) Derivados de 5-oxo-pirrolidina como agonistas de prostaglandinas
PE20010817A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
TR200003383T2 (tr) HIV ve diğer virüs enfeksiyonlarının tedavisine yönelik bileşimler.
PE20080716A1 (es) Coterapia constituida por un derivado de heterociclosulfamida benzofusionado y uno o varios agentes anticonvulsivantes y/o antilepticos
CO5040216A1 (es) Agonistas de adenosina a 1, proceso para su preparacion y composiciones farmaceuticas que los contienen
HK1035724A1 (en) Compounds as selective agonists at alpha 2B or 2B/2C adrenergic receptors.
EA200600188A1 (ru) Производные пиримидин-2,4-диона и их применение в качестве антагонистов рецепторов гонадолиберина
MA30652B1 (fr) Composes organiques
CO5210903A1 (es) Composiciones novedosas de mezcla de aceite
AP2001002307A0 (en) B3 adrenergic receptor agonists and uses thereof.
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
NZ509239A (en) 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
RS51249B (sr) Upotreba derivata sulfonamida sa benzo-fuzionisanim heterociklom za tretman bola
EP1445258A4 (en) ACTIVATOR OF THE PEROXISOMPROLIFERATOR-ACTIVATED RECEPTOR DELTA
AR070336A1 (es) Derivado tiazol y su uso como inhibidor de vap-1
PE20020844A1 (es) Derivados de imidazolilo como inhibidores del factor de liberacion de la corticotropina
PE119099A1 (es) Metodo para aumentar el volumen oseo utilizando agonistas selectivos fp que no ocurren naturalmente
PE71599A1 (es) Inhibidores de proteasas
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
NZ508560A (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
PE20001552A1 (es) Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo
BR0205812A (pt) Benzimidazois úteis no tratamento da disfunção sexual

Legal Events

Date Code Title Description
AE Restoration of lapsed or forfeited application
FC Refusal